{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-010648","form_type":"8-K","ticker":null,"cik":"0001797768","company_name":"Kinnate Biopharma Inc.","filed_at":"2024-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.565299+00:00","generated_at":"2026-06-05T05:43:26.232851+00:00","sec_items":["1.01","2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kinnate sells pan-RAF inhibitor exarafenib to Pierre Fabre for up to $31M","bullets":["Sold global rights to exarafenib and pan-RAF assets to Pierre Fabre for up to $31M ($500K at closing, $30.5M contingent).","Pierre Fabre assumes up to $5M in trade payables and 100% of ongoing program costs.","Transaction closed upon signing on Feb 27, 2024; no closing conditions.","Stockholders to receive net proceeds from $30.5M contingent payment if XOMA deal closes and proceeds received within 5 years.","$500K closing payment covers transaction expenses; no net proceeds to stockholders from that."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-010648","json":"https://secwatch.observer/filing/0001140361-24-010648.json","markdown":"https://secwatch.observer/filing/0001140361-24-010648.md","text":"https://secwatch.observer/filing/0001140361-24-010648.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1797768/000114036124010648/0001140361-24-010648-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1797768/000114036124010648/ny20021737x4_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T05:43:26.232851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a19a08bd04202541576824d82ac4ba28925b78f","claim":"Kinnate Biopharma Inc. completed a disposition involving Pierre Fabre Médicament, SAS for up to $31.0 million, consisting of $500,000 at closing (closed 2024-02-27).","evidence_excerpt":"exarafenib and other pan-RAF assets and will assume 100% of the ongoing program and costs associated with these assets. The Company will receive a total consideration of up to $31.0 million, consisting of $500,000 at closing, and an additional $30.5 million contingent upon the earlier of (i) the dosing of the first patient in the first pivotal trial for exarafenib","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000114036124010648/0001140361-24-010648-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Pierre Fabre Médicament, SAS"},{"label":"Consideration","value":"up to $31.0 million, consisting of $500,000 at closing"},{"label":"Closing","value":"2024-02-27"}],"fact_type":"ma_transaction"},{"claim_id":"040019d43c5b54a0231f4c46882c6f00245f640b","claim":"Kinnate Biopharma Inc. entered into Purchase Agreement with Pierre Fabre Médicament, SAS valued at up to $31.0 million (effective 2024-02-27).","evidence_excerpt":"On February 27, 2024, Kinnate Biopharma Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) by and among the Company and Pierre Fabre Médicament, SAS (“Pierre Fabre”), pursuant to which it sold the global rights to its investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets to Pierre Fabre, subject to the terms and conditions of the Purchase Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000114036124010648/0001140361-24-010648-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Pierre Fabre Médicament, SAS"},{"label":"Value","value":"up to $31.0 million"},{"label":"Effective","value":"2024-02-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}